GLP-1 drugs crushed the human obesity market so hard that venture capital looked around and said what else is fat. The answer: your cat. Startups are now testing weight-loss injections for pets because nothing says disruption like monetizing the fact that you overfeed an animal that cannot open its own food container.
Pet owners spent years turning cats into diabetic ottomans by free-feeding kibble engineered in laboratories to trigger dopamine responses. Now those same owners will pay monthly subscriptions to inject those cats with pharmaceuticals. The cycle is perfect. Create the problem. Sell the solution. Call it longevity.
Pet-food giants watched this happen and leaned into longevity products, which is corporate speak for expensive food that makes you feel less guilty about your cat's prediabetes. The pitch writes itself. Your pet deserves to live forever. Also your pet is morbidly obese because you have no impulse control. Here is a $90 bag of senior formula.
Retail traders will see this headline and immediately search for ticker symbols. They will find some microcap pet pharma company trading at four dollars. They will buy calls. They will tell themselves this is early-stage Amazon. It is not. It is a company that wants to give semaglutide to a species that spends sixteen hours a day sleeping and has zero concept of body image.
The real innovation is not the drug. It is convincing people that their cat needs it. Cats do not care if they are fat. They do not look in mirrors. They do not go to weddings. They sit on your laptop and knock glasses off counters at the exact same efficiency whether they weigh nine pounds or nineteen.
But someone will pay for it anyway, because throwing money at a problem you created is easier than putting the food bowl away.
Photo by Diana Polekhina on Unsplash
Leave a Comment